Trial Halted With Niacin Found Superior to Ezetimibe

“Unfortunately, the premature termination of the ARBITER 6-HALTS trial, the small number of patients studied, and the limited duration of follow-up preclude us from conclusively declaring niacin the adjunctive agent of choice on the basis of the evidence. A decrease of 0.014 mm in the carotid intima-media thickness over 14 months does not necessarily merit changes in our lipid-lowering guidelines at this time,” they said.

Dr. Taylor reports receiving lecture fees from Abbott. Dr. Blumenthal and Dr. Michos report no relevant conflicts of interest.

'We believe that prudent clinical practice currently favors the avoidance of ezetimibe.'

Source DR. TAYLOR